273 related articles for article (PubMed ID: 31505258)
1. HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control.
Canfell K; Kim JJ; Kulasingam S; Berkhof J; Barnabas R; Bogaards JA; Campos N; Jennett C; Sharma M; Simms KT; Smith MA; Velentzis LS; Brisson M; Jit M
Papillomavirus Res; 2019 Dec; 8():100184. PubMed ID: 31505258
[TBL] [Abstract][Full Text] [Related]
2. Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries.
Simonella L; Canfell K
Vaccine; 2015 Jan; 33(1):34-51. PubMed ID: 25171843
[TBL] [Abstract][Full Text] [Related]
3. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
4. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
7. A Qualitative Study of Parental Knowledge and Perceptions of Human Papillomavirus and Cervical Cancer Prevention in Rural Central Java, Indonesia: Understanding Community Readiness for Prevention Interventions.
Spagnoletti BRM; Bennett LR; Wahdi AE; Wilopo SA; Keenan CA
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2429-2434. PubMed ID: 31450917
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
9. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
[TBL] [Abstract][Full Text] [Related]
10. Public Health Benefits of Routine Human Papillomavirus Vaccination for Adults in the Netherlands: A Mathematical Modeling Study.
Matthijsse SM; Hontelez JA; Naber SK; Rozemeijer K; de Kok IM; Bakker R; van Ballegooijen M; van Rosmalen J; de Vlas SJ
J Infect Dis; 2016 Sep; 214(6):854-61. PubMed ID: 27330051
[TBL] [Abstract][Full Text] [Related]
11. Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines.
Brotherton JM; Jit M; Gravitt PE; Brisson M; Kreimer AR; Pai SI; Fakhry C; Monsonego J; Franceschi S
Int J Cancer; 2016 Aug; 139(3):510-7. PubMed ID: 26916230
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
13. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
[TBL] [Abstract][Full Text] [Related]
14. Towards cervical cancer eradication: joint force of HPV vaccination and HPV-based cervical cancer screening.
Poljak M
Clin Microbiol Infect; 2015 Sep; 21(9):806-7. PubMed ID: 26068650
[No Abstract] [Full Text] [Related]
15. Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine.
Monsonego J; Cortes J; Greppe C; Hampl M; Joura E; Singer A
Vaccine; 2010 Nov; 28(51):8065-72. PubMed ID: 20971114
[TBL] [Abstract][Full Text] [Related]
16. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.
Setiawan D; Luttjeboer J; Westra TA; Wilschut JC; Suwantika AA; Daemen T; Atthobari J; Wilffert B; Postma MJ
Expert Rev Vaccines; 2015 Apr; 14(4):589-604. PubMed ID: 25482311
[TBL] [Abstract][Full Text] [Related]
18. Sociodemographic factors predicting mother's cervical screening and daughter's HPV vaccination uptake.
Spencer AM; Roberts SA; Brabin L; Patnick J; Verma A
J Epidemiol Community Health; 2014 Jun; 68(6):571-7. PubMed ID: 24567443
[TBL] [Abstract][Full Text] [Related]
19. Can male vaccination reduce the burden of human papillomavirus-related disease in the United States?
Low GM; Attiga YS; Garg G; Schlegal R; Gallicano GI
Viral Immunol; 2012 Jun; 25(3):174-86. PubMed ID: 22691099
[TBL] [Abstract][Full Text] [Related]
20. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
